Table 2.

Glycemic outcomes, lipids and liver enzymes in patients with IGT, at baseline and after 12 weeks’ treatment or placebo

Variables	Baseline			12 wk.
	Control	Treated	p-value	Control	p-value	Treated	p-value
Fasting-glucose (mmol/l)	6.7 ± 0.4	6.0 ± 0.3	0.370	6.1 ± 0.4	0.205	6.1 ± 0.4	0.735
Fasting-insulin (mlE/l)	11.1 ± 2.0	9.8 ± 2.1	0.481	8.5 ± 1.6	0.034*	9.0 ± 2.5	0.284
HbA1c (mmol/mol)	40.1 ± 2.4	39.6 ± 1.3	0.815	40.1 ± 1.8	0.786	40.2 ± 1.6	0.320
Cholesterol (mmol/l)	4.5 ± 0.2	4.9 ± 0.4	0.673	4.4 ± 0.2	0.670	4.6 ± 0.3	0.482
LDL Cholesterol (mmol/l)	2.7 ± 0.2	3.2 ± 0.4	0.606	2.6 ± 0.3	0.528	2.9 ± 0.2	0.553
HDL Cholesterol (mmol/l)	1.5 ± 0.1	1.4 ± 0.1	0.888	1.5 ± 0.1	0.774	1.4 ± 0.1	0.414
Triglycerides (mmol/l)	1.1 ± 0.1	1.1 ± 0.1	0.888	1.0 ± 0.2	0.686	1.0 ± 0.1	0.101
ASAT (μkat/l)	0.38 ± 0.04	0.40 ± 0.05	0.888	0.38 ± 0.04	0.752	0.41 ± 0.05	0.445
ALAT (μkat/l)	0.39 ± 0.07	0.50 ± 0.09	0.481	0.38 ± 0.08	0.528	0.49 ± 0.09	0.799
ALP (μkat/l)	0.89 ± 0.05	1.04 ± 0.13	0.541	0.86 ± 0.06	0.161	1.10 ± 1.28	0.128
GT (μkat/l)	0.37 ± 0.07	0.58 ± 0.15	0.370	0.36 ± 0.06	0.674	0.71 ± 0.25	0.313
Bilirubin (μmol/l)	9.2 ± 1.1	9.9 ± 1.6	0.963	8.5 ± 1.1	0.197	11.6 ± 2.0	0.087
Pk (INR)	1.04 ± 0.02	1.0 ± 0.02	0.888	1.01 ± 0.02	0.157	1.0 ± 0.02	0.317

Significant differences between the control and treated group in glycemic outcomes, lipids and liver enzymes were evaluated at baseline with the Mann-Whitney U test.

Significant differences within the groups in glycemic outcomes, lipids and liver enzymes were evaluated at 12 wk. with the Wilcoxons signed rank test, *p < 0.05.

Values are reported as means ± SD.